[go: up one dir, main page]

EA033538B1 - Композиции и способы усиления иммунного ответа на кишечные патогены - Google Patents

Композиции и способы усиления иммунного ответа на кишечные патогены

Info

Publication number
EA033538B1
EA033538B1 EA201591798A EA201591798A EA033538B1 EA 033538 B1 EA033538 B1 EA 033538B1 EA 201591798 A EA201591798 A EA 201591798A EA 201591798 A EA201591798 A EA 201591798A EA 033538 B1 EA033538 B1 EA 033538B1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptide
methods
compositions
immune responses
enhancing immune
Prior art date
Application number
EA201591798A
Other languages
English (en)
Other versions
EA201591798A1 (ru
Inventor
Lisa Bielke
Sherryll Layton
Billy Hargis
Neil R Pumford
Olivia B Faulkner
Luc Berghman
Daad Abi-Ghanem
Original Assignee
Univ Arkansas
Texas A & M Univ Sys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas, Texas A & M Univ Sys filed Critical Univ Arkansas
Publication of EA201591798A1 publication Critical patent/EA201591798A1/ru
Publication of EA033538B1 publication Critical patent/EA033538B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к вакцинным векторам, способным вызывать иммунный ответ на кишечные бактерии, и к способам их применения. Вакцинные векторы включают полинуклеотид, кодирующий полипептид PAL. Полипептид PAL может экспрессироваться на поверхности вакцинного вектора. Вакцинный вектор также может включать второй полипептид, кодирующий иммуностимулирующий полипептид, такой как полипептид CD154 или полипептид HMGB1.
EA201591798A 2013-03-15 2014-03-14 Композиции и способы усиления иммунного ответа на кишечные патогены EA033538B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790301P 2013-03-15 2013-03-15
PCT/US2014/027416 WO2014152508A1 (en) 2013-03-15 2014-03-14 Compositions and methods of enhancing immune responses to enteric pathogens

Publications (2)

Publication Number Publication Date
EA201591798A1 EA201591798A1 (ru) 2016-06-30
EA033538B1 true EA033538B1 (ru) 2019-10-31

Family

ID=51581229

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591798A EA033538B1 (ru) 2013-03-15 2014-03-14 Композиции и способы усиления иммунного ответа на кишечные патогены

Country Status (18)

Country Link
US (3) US10376571B2 (ru)
EP (2) EP3578190A1 (ru)
JP (1) JP6530742B2 (ru)
KR (1) KR102239207B1 (ru)
CN (1) CN105142653B (ru)
AR (1) AR095313A1 (ru)
AU (1) AU2014239557B2 (ru)
BR (1) BR112015023024B1 (ru)
CA (1) CA2906079C (ru)
CL (2) CL2015002741A1 (ru)
EA (1) EA033538B1 (ru)
HK (1) HK1219045A1 (ru)
MX (1) MX376350B (ru)
MY (1) MY173901A (ru)
PH (1) PH12015502135A1 (ru)
SG (1) SG11201507421XA (ru)
WO (1) WO2014152508A1 (ru)
ZA (1) ZA201506466B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2009059298A2 (en) * 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
ES2968398T3 (es) 2013-02-14 2024-05-09 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria
EP3578190A1 (en) * 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
TWI843057B (zh) * 2016-05-03 2024-05-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
CN106124772B (zh) * 2016-06-15 2018-05-04 金华职业技术学院 一种基于omp18检测空肠弯曲菌的elisa检测试剂盒及其应用
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2018281306A1 (en) * 2017-06-07 2020-01-16 Spark Therapeutics, Inc. Enhancing agents for improved cell transfection and/or rAAV vector production
US20210369836A1 (en) * 2020-05-26 2021-12-02 Synlogic Operating Company, Inc. Surface display of proteins on recombinant bacteria and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166788A1 (en) * 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
WO2011156619A2 (en) * 2010-06-09 2011-12-15 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU664360B2 (en) 1991-03-05 1995-11-16 Wellcome Foundation Limited, The Expression of recombinant proteins in attenuated bacteria
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
DE69233402T3 (de) 1991-10-25 2009-06-25 Immunex Corp., Seattle Neue cytokine
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
EP0659086B1 (en) 1992-09-04 1998-11-11 The University of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
DK0812206T3 (da) 1995-03-01 2002-09-09 Immunex Corp Fremgangsmåde til stimulering af en immunrespons
AU693713B2 (en) 1995-06-07 1998-07-02 Immunex Corporation CD40L mutein
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
CA2313805A1 (en) 1997-12-19 1999-07-01 Immunex Corporation Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
IT1299583B1 (it) 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
CA2341349C (en) 1998-09-04 2013-12-10 Creatogen Aktiengesellschaft Attenuated cells comprising sp12 mutants, carriers and compositions containing same, methods of production and uses thereof
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
CA2369820A1 (en) 1999-04-16 2000-10-26 Frank Dicker Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
WO2001013948A1 (en) * 1999-08-20 2001-03-01 The General Hospital Corporation Outer membrane protein a, peptidoglycan-associated lipoprotein, and murein lipoprotein as therapeutic targets for treatment of sepsis
AU1084901A (en) 1999-10-14 2001-04-23 Martha S. Hayden-Ledbetter Dna vaccines encoding antigen linked to a domain that binds cd40
EP1112747B1 (en) 1999-12-28 2004-06-16 Akzo Nobel N.V. Salmonella vaccine not inducing antibodies against flagellin or flagella
WO2001055317A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2399790C (en) 2000-02-02 2012-10-30 Ralph A. Tripp Cd40 ligand adjuvant for respiratory syncytial virus
WO2001070247A2 (en) 2000-03-17 2001-09-27 Pharmacia & Upjohn Company Salmonella vaccine materials and methods
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
AU2001273009A1 (en) 2000-06-26 2002-01-08 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
AU2002221780A1 (en) 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US20030060410A1 (en) 2001-05-15 2003-03-27 North Shore Long Island Jewish Research Institute Use of HMG fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CA2447593C (en) 2001-05-15 2014-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
WO2003051383A2 (de) 2001-12-19 2003-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
PL208287B1 (pl) 2001-12-21 2011-04-29 Immunex Corp Polipeptyd fuzyjny, sposób jego wytwarzania oraz kodujący go kwas nukleinowy, komórka gospodarza, rekombinowany wektor oraz sposób jego konstruowania
US6929798B2 (en) 2002-02-13 2005-08-16 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
ATE556596T1 (de) 2002-04-15 2012-05-15 Univ St Louis Regulierte attenuierung von lebendimpfstoffen zur verbesserung der kreuzimmunitätsschutzfunktion
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
EP1569684A4 (en) 2002-11-20 2006-08-02 Critical Therapeutics Inc USE OF HMGB FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
EP1567544A4 (en) 2002-11-20 2009-07-22 Long Island Jewish Res Inst USE OF HMGB POLYPEPTIDES TO INCREASE IMMUNE RESPONSES
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
WO2005035570A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein
PL1694697T3 (pl) 2003-11-21 2011-05-31 Ace Biosciences As Zlokalizowane na powierzchni polipeptydy campylobacter jejuni
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
WO2005058950A2 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
US20070128183A1 (en) 2004-04-27 2007-06-07 Intercell Ag Td antigens
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
WO2006083301A2 (en) 2004-06-17 2006-08-10 Medimmune, Inc. Immunogenic compositions comprising hmgb1 polypeptides
EP1814576A2 (en) 2004-07-20 2007-08-08 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
JP5269412B2 (ja) 2004-10-07 2013-08-21 アルゴス セラピューティクス，インコーポレイティド 成熟樹状細胞組成物およびその培養方法
GB0423681D0 (en) 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
US20060286074A1 (en) 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
EP1909834A2 (en) 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
SI1949913T1 (sl) 2005-10-07 2011-02-28 Proyecto Biomedicina Cima Sl Imunsko stimulacijska kombinacija za zaĺ äśito in zdravljenje hepatitisa c
JP2009514536A (ja) 2005-11-07 2009-04-09 シドニー キンメル キャンサー センター Ｃｄ４０リガンド融合蛋白質ワクチン
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
WO2007130725A2 (en) 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
CU23576A1 (es) 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
WO2007106073A2 (en) 2006-03-02 2007-09-20 University Of Massachusetts Modified pathogens for use as vaccines
CN101064542B (zh) 2006-04-30 2010-12-08 中兴通讯股份有限公司 Mimo ofdm系统中发射天线选择与自适应调制方法
PL2059256T3 (pl) * 2006-08-11 2017-02-28 Life Sciences Research Partners Vzw Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
EP2066339B1 (en) 2006-09-18 2014-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses
US20100292309A1 (en) 2007-03-08 2010-11-18 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
NZ585776A (en) 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
WO2009059298A2 (en) 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
US20120093848A1 (en) * 2009-06-26 2012-04-19 Vectorite Biomedica Inc. Immunogenic composition comprising peptides derived from cytomegalovirus and the use thereof
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
WO2013071298A1 (en) 2011-11-11 2013-05-16 Nutrition Physiology Company, Llc Lactic acid bacteria and their use as dietary supplementals for poultry
EP2809347A1 (en) 2012-02-01 2014-12-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Campylobacter immunogenic compositions and uses thereof
EA039237B1 (ru) 2012-10-29 2021-12-21 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Применение маннозилированного хитозана в качестве адъюванта в составе вакцин для пероральной или мукозной доставки
ES2968398T3 (es) 2013-02-14 2024-05-09 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria
EP3578190A1 (en) * 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166788A1 (en) * 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
WO2011156619A2 (en) * 2010-06-09 2011-12-15 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FUCHS et al. "Targeting Recombinant Anibodies to the Surface of Escherichia coli: Fusion to a Peptidoglycan Associated Lipoprotein," Nature, 01 December 1991 (01.12.1991), vol. 9, p. 1-4, entire document *
GODLEWSKA et al. "Peptidoglycan-associated lipoprotein(Pal)of Gram-negative bacteria: function, structure, role in pathogenesis and potential application in immunoprophylaxis," FEMS Microbiol Lett, 10 June 2009 (10.06.2009), vol. 298, p. 1-11, entire document *
HARGIS, BILLY "Live Recombinant Salmonella Vaccination with Novel Universal Antigen Presentation and Immune Potentiation," USDA Grant Project Status, 14 January 2012 (14.01.2012), Retrieved from the lnternet:<http://portal.nifa.usda.gov/web/crisprojectpages/0211471-live-recombinant-salmonella-vaccination-with-novel-universal-antigen-presentation-and-immune-potentiation.html> on 18 June 2014 (18.06.2014), entire document *
LAYTON et al. "Evaluation of Salmonella-Vectored Campylobacter Peptide Epitopes for Reduction of Campylobacter jejuni in Broiler Chickens," Clinical and Vaccine Immunology, 01 March 2011 (01.03.2011), vol. 18, № 3, p. 449-454, entire document *

Also Published As

Publication number Publication date
US20190351042A1 (en) 2019-11-21
JP2016515133A (ja) 2016-05-26
KR20150130480A (ko) 2015-11-23
CL2017002971A1 (es) 2018-03-16
ZA201506466B (en) 2023-05-31
PH12015502135B1 (en) 2016-01-25
BR112015023024A2 (pt) 2017-11-14
CN105142653A (zh) 2015-12-09
EP3578190A1 (en) 2019-12-11
AU2014239557A2 (en) 2016-01-14
EP2968423A4 (en) 2016-11-09
MY173901A (en) 2020-02-26
CA2906079C (en) 2022-08-23
AU2014239557B2 (en) 2019-01-03
CL2015002741A1 (es) 2016-02-12
JP6530742B2 (ja) 2019-06-12
WO2014152508A1 (en) 2014-09-25
US10376571B2 (en) 2019-08-13
US10716840B2 (en) 2020-07-21
US20160038581A1 (en) 2016-02-11
BR112015023024B1 (pt) 2022-04-19
MX376350B (es) 2025-03-07
NZ711761A (en) 2021-08-27
CA2906079A1 (en) 2014-09-25
AR095313A1 (es) 2015-10-07
AU2014239557A1 (en) 2015-10-15
PH12015502135A1 (en) 2016-01-25
US20200297832A1 (en) 2020-09-24
MX2015012855A (es) 2016-07-21
EA201591798A1 (ru) 2016-06-30
US11013792B2 (en) 2021-05-25
SG11201507421XA (en) 2015-10-29
EP2968423A1 (en) 2016-01-20
KR102239207B1 (ko) 2021-04-09
HK1219045A1 (zh) 2017-03-24
CN105142653B (zh) 2019-11-15

Similar Documents

Publication Publication Date Title
EA033538B1 (ru) Композиции и способы усиления иммунного ответа на кишечные патогены
MX2018001213A (es) Nuevos metodos para inducir una respuesta inmunitaria.
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
PH12016500388A1 (en) Gitr antigen binding proteins
IL248483A0 (en) Different strains of Listeria recombinant vaccines and methods for their production
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
IN2014KN03063A (ru)
IL253610A0 (en) Keeping voltage in an iron nitride magnet
IL251624A0 (en) Recombinant immunogenic Listeria strains and their use as cancer immunotherapy methods
IL258563A (en) Recombinant Listera vaccine strains and methods for their use in cancer immunotherapy
WO2016126876A3 (en) Listeria-based adjuvants
EA201591488A1 (ru) Композиции и способы усиления иммунных ответов на eimeria или ограничения инфекции eimeria
MD4548B1 (ru) Полипептиды которые связываются к CX3CR1
NZ601609A (en) Vaccine vectors and methods of enhancing immune responses
TN2014000518A1 (en) Reassortant btv and ahsv vaccines
HK1254514A1 (zh) 用於增强疫苗接種免疫反應的方法及組合物
IL245509B (en) Compositions and methods for inducing an enhanced immune response using pox virus vectors
PH12018500201A1 (en) Enhanced immune response in porcine species
WO2016075305A3 (en) Peptides derived from acinetobacter baumannii and their use in vaccination
WO2014152271A8 (en) Viral proteins as immunomodulatory agents and vaccine components